UBS Adjusts Integra LifeSciences Price Target to $14 From $19
UBS has lowered its price target for Integra LifeSciences Holdings Corporation from $19 to $14 while maintaining a Neutral rating on the stock.
Stocks · News reference
Integra LifeSciences Reports Third Quarter 2026 Financial Results
Integra LifeSciences Holdings Corporation announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $411.2 million.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Truist Adjusts Price Target on Integra LifeSciences to $13 From $15
Truist has lowered its price target for Integra LifeSciences Holdings Corporation from $15 to $13 while maintaining a Hold rating.
JP Morgan Lowers Price Target for Integra LifeSciences
JP Morgan has reduced its price target for Integra LifeSciences Holdings Corporation from $17.00 to $14.00 per share.